Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide

Axoltis Pharma’s phase 2 trial for amyotrophic lateral sclerosis may have missed its primary endpoint, but the French biotech has pointed to secondary endpoints to justify persevering with the synthetic peptide.